#### COVID-19 in Pakistan: A national analysis of five pandemic waves

1

Short title: COVID-19 waves in Pakistan 2 3 Taimoor Ahmad<sup>1</sup>, Mujahid Abdullah<sup>1</sup>, Abdul Mueed<sup>1</sup>, Faisal Sultan<sup>2,3</sup>, Ayesha Khan<sup>1</sup>, 4 Adnan Ahmad Khan<sup>2,4\*</sup> 5 6 <sup>1</sup>Akhter Hameed Khan Foundation, Islamabad, Pakistan 7 8 <sup>2</sup>Ministry of National Health Services, Regulation and Coordination, Islamabad, Pakistan <sup>3</sup>Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan 9 <sup>4</sup>Research and Development Solutions, Islamabad, Pakistan 10 11 \*Corresponding Author 12 Email: adnan@resdev.org 13 **Disclosures:** 14 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation 15 [grant number: INV-025171]. Under the grant conditions of the Foundation, a Creative 16 Commons Attribution 4.0 Generic License has already been assigned to the Author 17 Accepted Manuscript version that might arise from this submission. 18 19 20 21 22 23 24

### **ABSTRACT**

**Objectives** 

25

26

28

29

30

31

32

34

35

36

37

38

39

40

41

42

43

45

27 The COVID-19 pandemic showed distinct waves where cases ebbed and flowed. While

each country had slight, nuanced differences, lessons from each wave with country-

specific details provides important lessons for prevention, understanding medical

outcomes and the role of vaccines. This paper compares key characteristics from the five

different COVID-19 waves in Pakistan.

#### Methods

We used specific criteria to define COVID-19 waves, and key variables such as COVID-

19 tests, cases, and deaths with their rates of change to the peak and then to the trough

were used to draw descriptive comparisons. Additionally, a linear regression model

estimated daily new COVID-19 deaths in Pakistan.

#### Results

Pakistan saw five distinct waves, each of which displayed the typical topology of a

complete infectious disease epidemic. The time from wave-start to peak became

progressively shorter, and from wave-peak to trough, progressively longer. Each wave

appears to also be getting shorter, except for wave 4, which lasted longer than wave 3. A

one percent increase in vaccinations increased daily new COVID-19 deaths by 0.10%

(95% CI: 0.01, 0.20) in wave 4 and decreased deaths by 0.38% (95% CI: -0.67, -0.08) in

44 wave 5.

#### Conclusion

Each wave displayed distinct characteristics that must be interpreted in the context of the level of response and the variant driving the epidemic. Key indicators suggest that COVID-19 preventive measures kept pace with the disease. Waves 1 and 2 were mainly about prevention and learning how to clinically manage patients. Vaccination started late during Wave 3 and its impact became apparent on hospitalizations and deaths in Wave 5. The impact of highly virulent strains Alpha/B1.1.7 and Delta/B.1.617.2 variants during Wave 3 and milder but more infectious Omicron/BA.5.2.1.7 are apparent.

## INTRODUCTION

In Pakistan, the first case of COVID-19, a novel and little-understood disease, was detected on February 26, 2020. Being a developing country with limited resources, crumbling health infrastructure and low health expenditure (1), Pakistan has no past experience with pandemics and a high burden of communicable diseases (2). As of February 23, 2022, the country had fully vaccinated 43% of its total population (3) and the Omicron variant of COVID-19 was the dominant strain (4). These factors make Pakistan a high-risk country, with a large pool of infection-susceptible people.

The emergence of COVID-19 has arguably been the biggest social and economic disruption in Pakistan in recent history. The pandemic has largely manifested itself in five distinct waves each of which have a rise, plateau and trough in cases, followed by a period of dormancy, after which the incidence of COVID-19 infections begins to rise again.

Thus, each individual wave follows a four stage pattern followed by endemicity that has

been seen for many infectious disease epidemics (12). Beyond anecdotal observation,

there is evidence that this is happening with COVID-19 as well (11). What sets COVID-

19 apart is that after completion of an individual wave, a new one would come along shortly, rather than much long, for example, annual, recurrences for influenza etc. This pattern has been seen all across the globe (5–10) with the timing of COVID-19 waves in different countries broadly coinciding (11). In this context, current literature on COVID-19 largely focuses on high-income countries during the initial waves (2,13-17), or aggregated at a regional level (5,6). Given the different capacities of countries to manage the pandemic (17), there is a need to explore the characteristics of the subsequent pandemic waves in a developing country context, preferably with granularity of a country-level analysis (2,13–17). To this end, this paper explores how each of the five waves of the COVID-19 pandemic in Pakistan differed from each other in terms of the total duration of each wave, the time from the start of each wave to its peak, and from its peak to the wave's trough; the length of time in between each wave; as well as key descriptive features like the total number of COVID-19 tests, COVID-19 cases, hospitalizations, deaths from COVID-19, and COVID-19 vaccinations in each wave. Additionally, this study statistically models the key factors that lead to deaths from COVID-19.

## **METHODS**

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

## **Criteria for COVID-19 waves**

We begin by retrospectively defining various time periods between 2020 and 2022 as distinct waves, based on existing literature (18). There are a total of 628 observations (daily set of indicators) across these five waves. Based on our criteria, the starting point of each COVID-19 wave is defined as the day with the lowest number of daily new COVID-

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

19 cases preceding a consistent rise in these cases, before the peak of the respective COVID-19 wave. The end of each wave is defined as the day with lowest number of daily new COVID-19 cases following a 7-day decline; this number also needed to be lower than the cases on any of the 7 days that followed it (Table 1). **Data and variables** In order to estimate the pattern for COVID-19 throughout the five waves in Pakistan, we have used time series of various daily indicators from April 3, 2020 to February 23, 2022. which categorized into following themes: Wave timespan i) ii) COVID-19 tests COVID-19 cases iii) Test-to-case ratio iv) V) COVID-19 positivity Hospitalization, treatment, and containment vi) vii) COVID-19 deaths viii) COVID-19 vaccination Policy environment ix) Several variables in the list above were transformed into ratios for the purpose of describing all five COVID-19 waves in Pakistan (Supplementary Table S1). The data for all but two of the above variables, second doses of COVID-19 vaccines administered and the Oxford Containment and Health Index for COVID-19, was compiled from daily national situation reports (Sitreps). These Sitreps are prepared by the National

Emergency Operations Centre (NEOC) in Islamabad, Pakistan. Data in these Sitreps have served as the basis for all major COVID-19 policy decisions in Pakistan.

The data for second doses of COVID-19 vaccines administered was sourced directly from the National Command & Operation Centre (NCOC), Islamabad, Pakistan, which is the government forum that brings together the ministries of Health and Planning along with the military to determine pandemic policy and to coordinate the response. Data for the Oxford Containment and Health Index is taken from a publicly available dataset from the University of Oxford's Blavatnik School of Governance (19). This dataset is compiled by using qualitative information about the non-pharmaceutical interventions (NPIs) in a country and quantifying them into an index. A detailed methodology of the index calculation can be found in a working paper by the Blavatnik school (20).

## **Model Specification**

For our model for COVID-19 deaths, we used a linear ordinary least square (OLS)

regression carried out using STATA 17. The data as well as the model was divided into

five distinct periods, representing the five waves of COVID-19 in Pakistan, as of February

2022. Regression analysis was performed separately on each wave and results were

compared with each other to make logical inferences.

Our dependent variable is the Daily New COVID-19 Deaths in Pakistan in logarithmic

form  $(LnY_t)$ ;  $\epsilon_t$  represents the error term capturing the effect of omitted variables. The

specification of our linear OLS regression model is as following:

$$Ln Y_t = \beta_0 + \beta_1 Ln X_{1t} + \beta_2 Ln X_{2t} + \beta_3 X_{3t} + \beta_4 X_{4t} + \beta_5 X_{5t} + \beta_6 X_{6t} + \beta_7 Ln X_{7t} + \epsilon_t$$

We have chosen seven independent variables:

i) Log of daily new COVID-19 cases with 21-day delay ( $LnX_{1t}$ ); 134 135 ii) Log of daily new COVID-19 tests with 28-day delay ( $LnX_{2t}$ ); iii) The Oxford Containment and Health Index for COVID-19 with 14-day delay  $(X_{3t})$ ; 136 iv) Time  $(X_{4t})$ ; 137 v) The number of people on ventilators as a proportion of the total admitted  $(X_{5t})$ ; 138 vi) The number of people on oxygen as a portion of the total admitted  $(X_{6t})$ ; 139 vii) Log of second doses of COVID-19 vaccines administered with 14- day delay ( 140  $LnX_{7t}$ ) 141 Daily new COVID-19 cases were regressed with a 21-day lag, since among those who 142 die from COVID-19 infection, death occurs between a median of 14 days (21) and 25 143 144 days (average of three weeks) after presenting symptoms (22,23). This is pertinent in the case of Pakistan, as most of the COVID-19 testing in the country has been symptomatic, 145 i.e., done when someone develops symptoms of COVID-19 and hence either voluntarily 146 147 gets tested or is prescribed by a medical professional to do so. Given the delay for daily new cases, daily new COVID-19 tests were regressed with a 148 delay of 28 days. This delay allows for the time it takes for someone to test positive for 149 COVID-19 and for their symptoms to worsen (for example, by escalating to 150 hospitalization, which takes nearly a week (24) before resulting in death. For vaccination, 151 152 a 14-day lag was taken, as immunity from vaccines is generally understood to develop two weeks or longer after receiving a shot (25–27). 153 The Oxford Containment and Health Index is calculated out of 100 which means strict 154 restrictions and a lower value indicate a smaller number of restrictions imposed on the 155

general population. This variable was regressed with a 14-day lag, as we assume that any new government restrictions will take approximately that long to have any effect. Additionally, the time variable is meant to capture any unmeasured or seasonal effects on COVID-19 deaths in Pakistan, such as an overall rate of increase/ decrease of daily deaths in each wave. We assume the error term is not correlated with any of the independent variable.

Diagnostic tests were performed on the estimated model to ensure the precision of the estimated coefficient: for heteroskedasticity, the Breusch-Pagan test was applied, whereas for serial correlation, the Durbin-Watson test was used. Variance inflation factor (VIF) was calculated for multicollinearity. Dickey-Fuller tests were run for each independent variable in our regression model. All of the variables were found to be stationary, fulfilling an important pre-requisite for our analysis (Table 1).

Table 1. Augmented Dicky-Fuller tests for unit roots

Variable	Test Statistics	P-Value	H₀: Random Walk
<b>Daily New COVID-19 Deaths</b>	-6.96	0.000	Stationary
Daily New COVID-19 Cases	-3.23	0.018	Stationary
Daily New COVID-19 Tests	-3.94	0.0017	Stationary
Oxford Containment and Health Index	-3.30	0.015	Stationary
Ventilator-admitted Ratio	-5.69	0.000	Stationary
Oxygen-Admitted Ratio	-3.00	0.034	Stationary
Fully Vaccinated People	-2.77	0.003	Stationary

## **RESULTS**

## **Summary statistics**

Pakistan experienced five distinct waves from 3<sup>rd</sup> April 2020 till 23<sup>rd</sup> February 2022 (Fig

1). The first wave lasted the longest (150 days), while the fifth one was the shortest (83

days). The fourth wave was remarkable for its relatively rapid upslope and a long tail, while the fifth wave showed the reverse pattern. The duration of each wave of COVID-19 in Pakistan was shorter than the preceding one apart from wave 4. After wave 1, each wave took less time to reach its peak and took longer to reach its trough apart from wave 5.

#### Figure 1. COVID-19 waves and daily new cases

The capacity to conduct tests expanded over time from an average of 17,142 tests daily during the first wave to 49,650 during fifth wave. The increase in the daily tests peaked during the fourth wave. The highest average daily number of cases (3147) were observed during the wave 3. The rate of increase of COVID-19 cases was highest during wave 4, but the rate of decline in cases after the peak of a wave was fastest during wave 5. Test to case ratio kept on increasing from 15 during the first wave to 57 during the fifth one. While total positivity varied across waves, the rate in daily change of positivity remained relatively unchanged apart from wave 2 and 3, where it is lower as compared to other waves (Table 2).

Table 2. Descriptive characteristics of each COVID-19 wave

Variables	Wave 1	Wave 2	Wave 3	Wave 4	Wave 5
Dates	April 3, 2020 to August 31, 2020	October 12, 2020 to February 16, 2021	February 23, 2021 to June 22, 2021	July 6, 2021 to November 29, 2021	December 7, 2021 to February 23, 2022
Main Variants of Concern (VOCs)	B.1	B.1.36	Alpha/ B1.1.7/ Delta/B.1.617.2	Delta/B.1.617.2	Omicron/BA.5.2.1.7
Timespan Duration of wave (days)	150	128	120	147	83
From wave Start till Peak (days)	72	57	55	31	52
From wave Peak till Trough (days)	78	71	65	116	31

**COVID-19 Tests** 

Total tests in the						
entire wave		2,571,244	4,638,219	5,458,041	7,148,130	4,120,909
Avg. Daily New COVID-19 Tests		17,142 (7,931)	36,236 (5,363)	45,484 (8,623)	48,627 (8341)	49,650 (7494)
Rate of Change of Daily New Tests	Up to Peak	380.9	216.5	701.1	836.6	540.4
Rate of Change of Daily New Tests	After Peak	-147.8	-101.0	-504.9	-286.4	-1137.6
COVID-19 Cases Total cases in the entire wave		293,752	246,188	377,668	320,333	221,825
Avg. Daily New COVID-19 Cases		1,958 (1,687)	1,923 (815)	3,147 (1,547)	2,179 (1548)	2,673 (2519)
Rate of Change of Daily New Cases	Up to Peak	93.9	60.9	94.0	161.0	155.9
Rate of Change of Daily New Cases	After Peak	-84.8	-40.0	-84.1	-48.0	-236.4
Test-to-Case Ratio		15	23	19	44	57
Average Test-to- Case Ratio		(15)	(11)	(11)	(38)	(56)
Rate of Change of Test-to-Case Ratio	Up to Peak	4.1	-1.1	-0.4	-1.13	-3.31
Rate of Change of Test-to-Case Ratio	After Peak	84.5	0.3	0.7	1.36	0.99
COVID-19 Positivity						
Avg. Daily Positivity Ratio during the wave		11.3% (6.4%)	5.2% (1.8%)	6.8% (2.9%)	4.2% (2.6%)	4.9% (4.1%)
Rate of Change of Positivity Ratio	Up to Peak	0.23	0.15	0.10	0.23	0.22
Rate of Change of Positivity Ratio	After Peak	-0.28	-0.10	-0.11	-0.07	-0.30
Hospitalization, Treatment, and						
Containment						
Avg. COVID-19 Hospital Admissions at any given time		3,817 (2,479)	2,187 (818)	3,970 (1,366)	3,396 (1,776)	1125 (423)
Avg. Length of Hospital Stay (days) <sup>a</sup>		-	13	11	9	5
Avg. Daily New Hospitalization to Daily New Case Ratio (%)		-	8.8 (2.4)	12.4 (3.5)	22.7 (10.7)	15.7 (10.8)
Avg. Daily Recoveries and Hospital Discharges Rate of Change of		1,870 (2,587)	1,746 (1,608)	2,990 (1,454)	2,272 (2,329)	2371 (3797)
Daily Recoveries and Hospital Discharges (non- cumulative)	Up to Peak	23.4	14.3	69.9	202.4	28.76

Rate of Change of						
Daily Recoveries						
and Hospital	After	-19.8	-6.6	-51.1	-57.7	-0.97
Discharges (non-	Peak					
cumulative)						
Avg. Stable-Admitted		67%	20%	14%	7%	9%
Ratio (%)		(27%)	(6%)	(5%)	(4%)	(4%)
Avg. Patients on		27%	68%			
Oxygen-Admitted		(23%)	(5%)	75% (5%)	83% (2%)	81% (3%)
Ratio (%)		(== , , ,	(5,5)			
Avg. Number of		865	1,521	2.005 (4.000)	2 902 (4 470)	918
Oxygen Beds in Use at any given time		(828)	(608)	2,995 (1,080)	2.803 (1,470)	(361)
Avg. Oxygen Beds		18%	15%	24%	20%	7%
Utilization Ratio (%)		(11%)	(6%)	(8%)	(10%)	(3%)
Avg. Number of			, ,	, ,	, ,	
Ventilators in Use at		214	249	429	336	109
any given time		(163)	(90)	(145)	(153)	(36)
Avg. Ventilator-		7%	11%	11%	10%	10%
Admission Ratio (%)		(4%)	(1%)	(0.6%)	(2%)	(1%)
Avg. Ventilators		17%	13%	20%	15%	5%
Utilization Ratio (%)		(10%)	(5%)	(7%)	(7%)	(2%)
COVID-19 Deaths						
Total COVID-19		0.004	F F07	0.400	0.007	4 404
deaths in the entire		6,204	5,537	9,423	6,287	1,401
wave		41.4	43.3	78.5	42.8	16.9
Avg. Daily New COVID-19 Deaths		(35.3)	(23.0)	(37.4)	(30.6)	(14.3)
Rate of Change of	Up	(33.3)	(23.0)	(37.4)	(30.0)	(14.5)
Daily New COVID-19	to	1.1	0.5	2.0	1.17	0.45
Deaths	Peak		0.0	2.0		0.10
Rate of Change of						
Daily New COVID-19	After	-1.0	0.1	-1.9	-0.44	-0.81
Deaths	Peak					
Avg. Daily New						
COVID-19 Deaths -		11%	27%	23%	10%	7%
Daily Hospitalization		(5%)	(13%)	(8%)	(4%)	(4%)
Ratio (%)						
Avg. Daily New COVID-19 Deaths –		23%	17%	18%	12%	13%
Ventilator in use		23% (17%)	(6%)	(5%)	(5%)	(8%)
Ratio (%)		(17 70)	(070)	(370)	(370)	(070)
Avg. Death-to-Case		2.2%	2.3%	2.8%	2.2%	1.1%
Ratio (%)		(0.8%)	(1.1%)	(1.2%)	(0.8%)	(1.0%)
COVID-19		,	, ,	, ,	,	
Vaccination <sup>b</sup>						
Total Administration						
of 2 <sup>nd</sup> doses of		-	-	3,136,386	45,294,948	45,667,572
Vaccine						
Avg. Daily New				26,356	308,129	550,212
Administration of 2 <sup>nd</sup> doses of Vaccine		-	=	(25,980)	(172,896)	(186,287)
Policy Environment					•	<u> </u>
Oxford Containment		58.8	62.4	65.7	58.1	58.6
and Health Index		(7.6)	(4.0)	(6.3)	(9.4)	(5.5)
			/	\ /	\ - /	\ /

<sup>190</sup> Standard deviations are reported in parentheses.

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

<sup>a</sup>Data for daily new COVID-19 hospitalizations was not available during wave 1. <sup>b</sup>COVID-19 vaccines were not being administered during waves 1 and 2. Hospitalizations were the highest for the first and the third wave and the least for the fifth, whereas duration of hospitalization fell linearly from an initial 13 days during the second wave to 5 days during the fifth. Hospitalizations became more specific over time in that, nearly two third of admitted patients during the first wave were stable, compared to 9% during the fifth one. The average stable-admitted ratio decreased continuously from wave 1 to wave 4 but increased slightly in wave 5. The rate at which people recovered from COVID-19 and/or were discharged from hospital was highest in wave 4 and slowest in wave 2. The average Oxygen Beds-Admitted Ratio continuously increasing in each wave, reaching its maximum value in wave 4. During the first wave 27% of all admissions required oxygen, 7% needed a ventilator, compared to 81% and 10% respectively during the fifth wave. The average oxygen bed utilization followed a declining trend except for the third wave (24%) and was lowest in the fifth wave (7%). The average Ventilators Utilization Ratio shows that all available ventilators were not fully utilized in any of the five waves. The highest ratio was in wave 3 (20%) and the lowest ratio was in wave 5 (5%). These two ratios suggest that most critical patients were put on oxygen for recovery and a small proportion of these people were transferred to ventilators. Deaths from COVID-19 were the highest during the third wave at 9,423, which also saw the highest daily number of deaths (78.5) and the highest rate of increase in daily deaths. Average daily deaths to hospitalization peaked during the second wave, while deaths to ventilator use was the highest during the first. Average death to case ratio was the highest for the third wave but was in the 2.2-2.8% range, with the exception of the fifth wave when it was 1.1%.

Pakistan's vaccination drive started towards the end of wave 2, but full vaccination (i.e., people receiving both their doses) did not occur until the beginning of wave 3. Consequently, total and daily new second dose of vaccine administered was highest in wave 5. Government restrictions, measured by the Oxford Health and Containment Index, appear to have been comparable in each wave.

### **Regression results**

The results indicate the daily new COVID-19 cases were a statistically significant determinant for daily new deaths in all five waves at 95% CI; a one-percentage increase in COVID-19 cases caused a 0.46- 0.69 % increase in deaths across the five waves (Table 3).

Table 3. Ordinary least squares (OLS) regression results for COVID-19 deaths

LOG (Daily New	(1)	(2)	(3)	(4)	(5)
COVID-19 Deaths)	Wave 1	Wave 2	Wave 3	Wave 4	Wave 5
LOG (Daily New	0.455*	0.685*	0.691*	0.677*	0.506*
COVID-19 Cases) – 21-day delay	[0.289,0.620]	[0.430,0.939]	[0.358,1.025]	[0.542,0.812]	[0.189,0.823]
LOG (Daily New	0.648*	0.308	-0.162	0.268	0.296
COVID-19 Tests) – 28-day delay	[0.260,1.037]	[-0.179,0.795]	[-0.645,0.322]	[-0.122,0.657]	[-0.771,1.364]
Oxford Containment	-0.027*	-0.009	0.012	0.017	-0.030
and Health Index – 14- day delay	[-0.050, -0.005]	[-0.030,0.012]	[-0.005,0.028]	[-0.006,0.040]	[-0.072,0.013]
Time	-0.035* [-0.042, -0.028]	-0.002 [-0.005,0.001]	-0.009* [-0.016, -0.002]	-0.005* [-0.010, -0.000]	0.011 [-0.008,0.030]
Ventilator-Admitted	-16.662*	0.555	-11.074	-14.092*	-15.681*
Ratio	[-29.406, -3.918]	[- 10.098,11.208]	[-25.332,3.183]	[-19.096, - 9.089]	[-27.872, -3.489]

Oxygen-Admitted Ratio	3.734* [0.788,6.680]	4.413* [1.848,6.979]	0.148 [-5.421,5.718]	0.640 [-2.558,3.838]	2.435 [-4.943,9.814]
LOG (Second doses administered) 14-day delay	-	-	0.073* [0.006,0.139]	0.104* [0.010,0.198]	-0.375* [-0.668, -0.083]
Constant	-1.222 [-4.180,1.736]	-6.707* [-10.447, - 2.967]	3.169 [-1.606,7.945]	-3.417 [-8.348,1.514]	-4.846 [-18.956,9.263]
Observations	122	128	104	147	83

\*Significant at a 95% CI or higher Newey West CI in parentheses

The daily new COVID-19 tests and Oxford Health and Containment Index, which records the presence of government NPIs and restrictions, were both found to be a statistically significant determinants of COVID-19 deaths in wave 1. Increasing daily new tests by 1% will reduce the daily deaths by 0.65% (95% CI: 0.26%, 1.04%). While increase in Oxford Health and Containment Index by 1 point will result in 0.03% reduction in daily new deaths (95% CI: -0.05%, -0.005%).

The time trend variable is statistically significant in wave 1, wave 3 and wave 4. The coefficients indicate that, on average, daily COVID-19 deaths decreased at a rate of 0.04% per day (95% CI: -0.04%, -0.03%) as time passed during wave 1. However, daily new deaths reduced at a rate of 0.01% per day during wave 3 (95% CI: -0.02%, 0.002%) and wave 4 (95% CI: -0.01%, 0.00%).

The ventilator to admitted ratio was statistically significant in wave 1, wave 4 and wave 5.

The coefficient remains negative throughout these three waves and significant at 95% CI.

The coefficients indicates that if ratio of patients on ventilator out of the admitted increases

than daily new deaths decrease by 14-17%.

Oxygen to admitted ratio is only significant in wave 1 and 2 at 95% CI, where the coefficient is positive. It means that if the ratio of oxygenated patient out of the total admitted increase than daily new deaths due to COVID-19 will increase by approximately 4%.

Lastly, the number of fully vaccinated people came out to be statistically significant in each of the last three waves. During wave 3, COVID-19 deaths increase by 0.07% (95% CI: 0.006,0.14) as percentage of fully vaccinated people increase by one addition percentage. This rate increased to 0.10% (95% CI: 0.006,0.14) during the wave 4. However, in the fifth wave, daily new deaths due to COVID-19 decrease by 0.38% (95% CI: -0.67, -0.08) as fully vaccinated people increases.

## **DISCUSSION**

Pakistan experienced 5 distinct waves from 3<sup>rd</sup> April 2020 to 23<sup>rd</sup> February 2022. Our analysis reflects both the evolution of Pakistan's response, as well as the differential impact of different variants of the virus shaped the contours and features of each wave. Pakistan experienced its initial wave earlier than other South Asian countries including India, Bangladesh, Sri Lanka and Nepal, while peaks for the subsequent waves coincided with those in other countries (31).

The upslope, as seen by the rate of change for testing and cases, was always steeper than during the downward slope of a wave. This pattern follows what is known about infectious epidemics in that cases rise quickly, plateau and then fall, slowly to an endemic state where a low ebb of infections persist in the community in definitely (12). In fact, each wave behaved as a typical epidemic caused by a distinct variant of the virus. Wave 1 was

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

dominated by B.1 variant, wave 2 by B.1.36 variant, the wave 3 by Alpha/B1.1.7 and Delta/B.1.617.2 variants, wave 4 had majority cases of the Delta/B.1.617.2 variant (28– 30) while wave 5 was driven by Omicron/BA.5.2.1.7 (4). A key challenge faced by Pakistan at the beginning of the pandemic was that there was little prior experience with any pandemic outbreak of such level. Although disease surveillance systems exist, they had not been scaled to manage case surveillance, hospital admissions, daily deaths, and eventually large-scale adult vaccination and event tracking. Pakistan has a federal system of governance where provinces provide health services while the federal ministry provides guidance and coordination. In addition, considerable curative care is in the private sector. To address the potential difficulties in mounting a unified national response to the disease in the face of this diversity, a National Action Plan for COVID-19 was formulated in March 2020 that placed the responsibility for the national response in a National Coordination Committee (NCC) that was headed by the Prime Minister and attended by all federal ministers. The NCC set national policy which was implemented by the National Command and Operation Centre (NCOC) that was co-headed by the military and civilian leadership (32). The NCOC coordinated the management of the extensive lockdowns, other key NPIs such as school closures, limited opening hours for essential businesses (examples of which included grocery stores and pharmacies), closure of borders, cancellation of public events and social gatherings (33,34). This was supported based on an elaborate data gathering and analysis system that that guided daily decisions. Wave 1 continued the longest and intervals became shorter between each successive wave. Each wave showed unique features, that were determined by the particular variant

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

that drove that wave, along with the larger context that included the type of the variant driving the wave, the extent and type of preventive interventions and eventually the availability of the vaccine. Pakistan's response to COVID-19 evolved over time. For example, Wave 1 had the highest positivity rates and the longest duration, in part due to low initial rates of testing, including very little contact tracing in the early days (35). As testing increased and mobility restrictions tightened, duration of Waves 2 and 3 became shorter. However, by the end of the second wave, intervention fatigue had set in. Implementation was laxer, and these factors contributed to more cases and deaths of any wave during Wave 3. Indeed, the Oxford Health and Containment Index was significant only during Wave 1 in terms of preventing deaths. In addition to preventive measures, the higher daily COVID-19 cases in waves 3, 4 and 5 may be attributed to highly transmissible Alpha (36,37), Delta (38,39) and Omicron (40) variants, and to easing of severe restrictions such as lockdowns and school closures (41). It is also possible that many cases were missed during Wave 1 due to limited testing. However, the stability of daily testing in waves 3 to 5 suggests a stable equilibrium between the testing system and how cases were being incident - the system was capturing most of the cases from previously recognized populations and locations. It is likely that undiagnosed cases and deaths were few, since as part of the national surveillance, teams kept abreast of burials in large and midsized towns and also periodically canvased opinion of general practitioners about upsurges in respiratory illnesses. On average, Pakistan had fewer cases per million population than neighboring

countries of India, Bangladesh, and Iran, as well as several of the developed countries (31).

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

As with prevention, clinical management of cases evolved over time. Initially most cases were hospitalized as seen by the high case to hospitalization ratio - only 27% of admissions required oxygen 7% required ventilators during the Wave 1. In fact, there was a correlation between deaths and oxygenation (which was mostly at hospitals) during waves 1 and 2, a pattern that was seen globally. However, with each succeeding wave, use of oxygen increased while ventilators fluctuated within a narrow range, as was also seen in India (52,53). Thus, even as COVID-19 hospitalizations peaked during Wave 3, hospitalization to case ratio increased, and average duration of hospitalization and the use of hospitals for simple oxygenation fell, suggesting hospitals, ICU and ventilators, were increasingly reserved only for the sickest (42). Deaths correlated best with a 21-day delay model rather than a 28-day one, suggesting that most deaths happened early after infection. Higher hospitalizations during the third wave may also have been attributed to the Alpha followed by Delta variants (43-45). By contrast the lower hospitalizations, length of stay and mortality during the fifth wave may be attributed to the Omicron variant that was seen worldwide (46,47), and specifically in South Africa (48) and Brazil (49) during the Omicron waves. Vaccination started halfway during wave 3 and more than half of the eligible population was fully vaccinated (3) by the fifth wave, and may have contributed to lower hospitalizations in Wave 5. Unlike COVID-19 induced major challenges to the healthcare capacity in various countries (50,51), Pakistan was able to build healthcare resources capacity to keep pace with the pandemic. Ventilator and oxygen utilization never exceeded 20% and 24% respectively in wave 3.

Vaccination drive started in Pakistan by the end of February 2021. Despite a slow start, vaccination picked up pace from 26,356 daily vaccinations in Wave 3 to 308,129 in the fourth wave as it was rolled-out to younger population and vaccine supply increased in the country. Average daily deaths did not reduce significantly due to vaccinations during the third and fourth waves (56,57) but showed marked reduction in hospitalizations and deaths towards the end of fourth and during the entire fifth wave (58). From our regression model, we found that daily new COVID-19 cases were statistically significant determinants of daily new deaths due to COVID-19. The association was also observed from the third wave as both cumulative cases and deaths were the highest, including the average daily deaths which were considerably higher than any other wave, as seen in other countries (54). Secondly, daily new deaths due to COVID-19 increased with patients on oxygenated beds while decreased with patients on ventilators in the initial waves, potentially due to high patients load in hospitals, critical patients were put on oxygen rather than ventilator. Fifth wave experienced the smallest number of daily COVID-19 deaths possibly because it was dominated by the Omicron variant (55).

# **LIMITATIONS**

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

There are a number of limitations associated with the data used in this paper. While the official data used for the analysis are disaggregated by sub-national level, demographic disaggregation, such as age or gender, are not available. This limits the analysis in terms of the implication of gender and age on COVID-19 deaths. The national data is compiled by aggregating the numbers for each subnational unit in Pakistan. However, such an analysis would be too extensive to depict and therefore our analysis does not account for sub-national differences. It is possible that distinctive cultures, behaviors and differences

in the stringency in enforcement of interventions vary between for regions and may in theory, influence the number of COVID-19 cases and deaths.

Similarly, data for hospitalizations is also unaccompanied by any information on comorbidities, as this information was not available beyond treating hospitals, losing a level of richness of analysis that includes such comorbidities. Also, data for daily new hospital admissions started becoming available towards the very end of wave 1. Consequently, the average length of hospital stay could not be calculated for this wave.

The official vaccination data available to us at the time of this analysis is not desegregated by the different types of available vaccines, for example Sinopharm, CanSino, Sputnik V and others. Differential impact of each vaccine on COVID-19 deaths in Pakistan would be informative. All of the above limitations notwithstanding, we are confident that this study provides crucial insights into the prevailing trends of COVID-19 in Pakistan in manner that is constructive.

## CONCLUSION

COVID-19 management in Pakistan kept pace with the spread of the disease during five distinct waves. We describe how these waves differed in terms of cases, hospitalizations and deaths and analyze potential reasons for these differences. These lessons, as well as limitations of our approach, provide important lessons for managing future pandemics.

### **REFERENCES**

1. Noreen N, Dil S, Ullah S, Niazi K, Naveed I, Khan NU, et al. Coronavirus disease (COVID-19) Pandemic and Pakistan; Limitations and Gaps. Limitations Gaps Glob Biosecurity [Internet]. 2020;1(3). Available from: https://jglobalbiosecurity.com/articles/63/galley/170/download/

- Babu GR, Khetrapal S, John DA, Deepa R, Narayan KMV. Pandemic
   preparedness and response to COVID-19 in South Asian countries. Int J Infect
   Dis [Internet]. 2021;104:169–74. Available from:
   https://doi.org/10.1016/j.ijid.2020.12.048
- 386 3. NCOC. Vaccine Statistics [Internet]. 2022 [cited 2022 Feb 23]. p. NCOC Official Website. Available from: https://covid.gov.pk/vaccine-details
- Badar N, Ikram A, Salman M, Umair M, Rehman Z, Ahad A, et al. Genomic
   characterization of SARS-CoV-2 from Islamabad, Pakistan by Rapid Nanopore
   sequencing. Available from: https://doi.org/10.1101/2022.02.17.480826
- 5. Coccia M. The impact of first and second wave of the COVID-19 pandemic in society: comparative analysis to support control measures to cope with negative effects of future infectious diseases. Environ Res [Internet].

  2021;197(April):111099. Available from:
  https://doi.org/10.1016/j.envres.2021.111099
- Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet [Internet]. 2021;397(10281):1265–75. Available from: http://dx.doi.org/10.1016/S0140-6736(21)00632-2
- 7. Iftimie S, Lopez-Azcona AF, Vallverdu I, Hernandez-Flix S, De Febrer G, Parra S, et al. First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. PLoS One. 2021;16(3 March 2021):1–13.
- Jalali SF, Ghassemzadeh M, Mouodi S, Javanian M, Kani MA, Ghadimi R, et al. Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran. Casp J Intern Med. 2020;11(2):S544–50.
- Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ,
   Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19
   vaccines: production, affordability, allocation, and deployment. Lancet. 2021 Mar
   13;397(10278):1023–34.
- Vanthomme K, Gadeyne S, Lusyne P, Vandenheede H. A population-based study on mortality among Belgian immigrants during the first COVID-19 wave in
   Belgium. Can demographic and socioeconomic indicators explain differential mortality? SSM Popul Heal [Internet]. 2021;14:100797. Available from: https://doi.org/10.1016/j.ssmph.2021.100797
- So MKP, Chu AMY, Tiwari A, Chan JNL. On topological properties of COVID-19:
   predicting and assessing pandemic risk with network statistics. Sci Rep [Internet].
   2021;11(1):1–14. Available from: https://doi.org/10.1038/s41598-021-84094-z
- 418 12. Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease
   419 epidemics: Implications for prevention strategies. J Infect Dis. 1996;174(SUPPL.
   420 2).
- 13. Sibiri H, Prah D, Zankawah SM. Containing the impact of COVID-19: Review of

- Ghana's response approach. Heal Policy Technol [Internet]. 2021;10(1):13–5.
- 423 Available from: https://doi.org/10.1016/j.hlpt.2020.10.015
- 14. Olufadewa II, Adesina MA, Ekpo MD, Akinloye SJ, Iyanda TO, Nwachukwu P, et al. Lessons from the coronavirus disease 2019 (COVID-19) pandemic response in
- China, Italy, and the U.S.: a guide for Africa and low- and middle-income
- countries. Glob Heal J [Internet]. 2021;5(1):56–61. Available from:
- 428 https://doi.org/10.1016/j.glohj.2021.02.003
- He D, Zhao S, Xu X, Lin Q, Zhuang Z, Cao P, et al. Low dispersion in the infectiousness of COVID-19 cases implies difficulty in control. BMC Public Health. 2020;20(1):2–5.
- 432 16. Van Nguyen Q, Cao DA, Nghiem SH. Spread of COVID-19 and policy responses 433 in Vietnam: An overview. Int J Infect Dis [Internet]. 2021;103:157–61. Available 434 from: https://doi.org/10.1016/j.ijid.2020.11.154
- 17. Sharma A, Borah SB, Moses AC. Responses to COVID-19: The role of
   governance, healthcare infrastructure, and learning from past pandemics. J Bus
   Res [Internet]. 2021;122(102):597–607. Available from:
   https://doi.org/10.1016/j.jbusres.2020.09.011
- Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ, et al. Comparison of the second and third waves of the COVID-19 pandemic in South Korea:
   Importance of early public health intervention. Int J Infect Dis [Internet].
   2021;104:742–5. Available from: https://doi.org/10.1016/j.ijid.2021.02.004
- 19. OxCGRT. OxCGRT COVID Policy Tracker Data [Internet]. 2021. Available from:
   https://github.com/OxCGRT/covid-policy-tracker/tree/master/data/timeseries
- 445 20. Hale T, Anania J, Angrist N, Boby T, Cameron-Blake E, Folco M Di, et al.
   446 Variation in government responses to COVID-19, Version 12.0 [Internet]. BSG
   447 Working Paper Series. 2021. Available from:
   448 https://covidtracker.bsg.ox.ac.uk/stringency-scatter
- Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of
   mortality following COVID-19 infection. Lancet Infect Dis [Internet].
   2020;20(7):773. Available from: http://dx.doi.org/10.1016/S1473-3099(20)30195-X
- 452 22. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al.
  453 Causes of death and comorbidities in hospitalized patients with COVID-19. Sci
  454 Rep [Internet]. 2021;11(1):1–9. Available from: https://doi.org/10.1038/s41598455 021-82862-5
- 456 23. Marschner IC. Estimating age-specific COVID-19 fatality risk and time to death by
  457 comparing population diagnosis and death patterns: Australian data. BMC Med
  458 Res Methodol [Internet]. 2021;21(1):1–10. Available from:
  459 https://doi.org/10.1186/s12874-021-01314-w
- 460 24. Asirvatham ES, Sarman CJ, Saravanamurthy SP, Mahalingam P,
   461 Maduraipandian S, Lakshmanan J. Who is dying from COVID-19 and when? An

- Analysis of fatalities in Tamil Nadu, India. Clin Epidemiol Glob Heal [Internet]. 2021;9:275–9. Available from:
- https://www.sciencedirect.com/science/article/pii/S2213398420302189
- Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121–30.
- 469 26. Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous prime-boost
  470 immunization with CoronaVac and Convidecia. medRxiv [Internet].
  471 2021;(20):2021.09.03.21263062. Available from:
  472 http://medrxiv.org/content/early/2021/09/06/2021.09.03.21263062.abstract
- Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T, Provstgaard-Morys S, et al.
   Safety and Immunogenicity Report from the Com-COV Study a Single-Blind

475 Randomised Non-

- Inferiority Trial Comparing Heterologous And
  Homologous Prime-Boost Schedules with An Adenoviral Vectored and
  mRNA COVID-19 Vaccine. SSRN Electronic Journal. 2021.
- Umair M, Ikram A, Rehman Z, Haider A, Badar N, Ammar M, et al. Genomic diversity of SARS-CoV-2 in Pakistan during fourth wave of pandemic. medRxiv [Internet]. 2021;92(51):2021.09.30.21264343. Available from: http://medrxiv.org/content/early/2021/10/03/2021.09.30.21264343.abstract
- Basheer A, Zahoor I. Genomic epidemiology of SARS-CoV-2 divulge B.1, B.1.36, and B.1.1.7 as the most dominant lineages in first, second, and third wave of SARS-CoV-2 infections in Pakistan. Microorganisms [Internet]. 2021 [cited 2022 Sep 21];9(12). Available from: https://doi.org/10.3390/microorganisms9122609
- Shakeel M, Irfan M, Nisa Z un, Farooq S, Ain N ul, Iqbal W, et al. Genome sequencing and analysis of genomic diversity in the locally transmitted SARS-CoV-2 in Pakistan. Transbound Emerg Dis [Internet]. 2022; Available from: http://tree.bio.ed.ac.uk/software/Fig.tree/
- 491 31. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al.
  492 Coronavirus Pandemic (COVID-19) [Internet]. OurWorldInData.org. 2020.
  493 Available from: https://ourworldindata.org/coronavirus
- National Institute of Health Pakistan. National Action Plan for Corona virus disease (COVID-19) Pakistan [Internet]. 2020. Available from: https://www.nih.org.pk/wp-content/uploads/2020/03/COVID-19-NAP-V2-13-March-2020.pdf
- Gul A. Pakistan Seals Borders, Shuts Schools, Bans Public Events Over
   Coronavirus. Voanews.com [Internet]. 2020 Mar 13;COVID-19 Pandemic.
   Available from: https://www.voanews.com/a/science-health\_coronavirus-outbreak\_pakistan-seals-borders-shuts-schools-bans-public-events-

502 over/6185785.html

- Chandir S, Siddigi DA, Setayesh H, Khan AJ. Impact of COVID-19 lockdown on 503 routine immunisation in Karachi, Pakistan. Lancet Glob Heal [Internet]. 504
- 2020;8(9):e1118–20. Available from: 505
- https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30290-506 4/fulltext 507
- 35. Habib M, Abbas M. Facing the Threat of COVID-19 in Pakistan: A Nation's 508 509 Dilemma. Value Heal Reg issues. 2021 May;24:90–5.
- 36. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing 510 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England The COVID-19 511
- Genomics UK (COG-UK) consortium. Nature [Internet]. 2021;593. Available from: 512
- https://doi.org/10.1038/s41586-021-03470-x 513
- 37. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. 514
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. 515
- Science (80- ) [Internet]. 2021;372(6538). Available from: 516
- 517 http://science.sciencemag.org/
- 518 38. Zhan Y, Yin H, Yin J-Y. (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. Int J Biol Sci [Internet]. 2022;2022(5):1844-51. Available 519 from: https://www.ijbs.com//creativecommons.org/licenses/by/4.0/ 520
- 521 39. Kumar S, Tripathi V, Zhang J, Hu Z, Huang X, Fu S, et al. Differences in Clinical Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected 522 Patients. Front Med | www.frontiersin.org [Internet]. 2019;1:792135. Available 523 from: www.frontiersin.org 524
- 40. 525 Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the 526 highly mutated SARS-CoV-2 Omicron variant. 2022; Available from: https://www.gisaid.org/ 527
- 528 41. Provinces announce easing lockdown even as Pakistan witnesses record rise in 529 coronavirus cases [Internet]. DAWN. 2020 [cited 2022 Aug 1]. Available from: https://www.dawn.com/news/1555575 530
- 42. Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences 531 in ICU admissions during the first and second COVID-19 wave in Germany 532 [Internet]. Vol. 9, The Lancet Respiratory Medicine. 2021 [cited 2022 Oct 7]. p. 533 534 e47–8. Available from: https://doi.
- 43. Twohiq KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. 535 Hospital admission and emergency care attendance risk for SARS-CoV-2 delta 536 (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. 537
- Lancet Infect Dis [Internet]. 2021; Available from: 538
- https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-539 8/fulltext 540
- Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the Delta 44. 541 542 Variant B.1.617.2 COVID-19. Clin Pr [Internet]. 2021;11:778–84. Available from: https://doi.org/10.3390/clinpract11040093 543

- 544 45. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in 545 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. 546 Lancet [Internet]. 2021 Jun 26 [cited 2022 Oct 7];397(10293):2461–2. Available 547 from: http://www.thelancet.com/article/S0140673621013581/fulltext
- 548 46. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol [Internet]. 2022 Jul 1 [cited 2022 Oct 7];94(7):2969–76. Available from: https://pubmed.ncbi.nlm.nih.gov/35246846/
- Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2
   Omicron Variant Severity in Ontario, Canada. JAMA [Internet]. 2022 Apr 5 [cited
   2022 Oct 7];327(13):1286–8. Available from:
   https://jamanetwork.com/journals/jama/fullarticle/2789408
- Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B.
   Characteristics and Outcomes of Hospitalized Patients in South Africa during the
   COVID-19 Omicron wave Compared with Previous waves. JAMA J Am Med
   Assoc. 2022 Feb 8;327(6):583–4.
- 49. Martins-Filho PR, de Souza Araújo AA, Quintans-Júnior LJ, Soares BDS, Barboza W de S, Cavalcante TF, et al. Dynamics of hospitalizations and in-hospital deaths from COVID-19 in northeast Brazil: a retrospective analysis based on the circulation of SARS-CoV-2 variants and vaccination coverage. Epidemiol Health [Internet]. 2022 [cited 2022 Oct 7];44:e2022036. Available from: https://pubmed.ncbi.nlm.nih.gov/35413166/
- 50. Mateen BA, Wilde H, Dennis JM, Duncan A, Thomas N, McGovern A, et al.
  Hospital bed capacity and usage across secondary healthcare providers in
  England during the first wave of the COVID-19 pandemic: a descriptive analysis.
  BMJ Open [Internet]. 2021 Jan 26 [cited 2022 Oct 7];11(1). Available from:
  https://pubmed.ncbi.nlm.nih.gov/33500288/
- 51. Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The Capacity of the Indonesian Healthcare System to Respond to COVID-19. Front Public Heal. 2021 Jul 7;9:887.
- 574 52. Kumar G, Mukherjee A, Sharma RK, Menon GR, Sahu D, Wig N, et al. Clinical profile of hospitalized COVID-19 patients in first & second wave of the pandemic: Insights from an Indian registry based observational study. Indian J Med Res [Internet]. 2021 May 1 [cited 2022 Oct 7];153(5–6):619. Available from: /pmc/articles/PMC8555588/
- 53. Budhiraja S, Indrayan A, Aggarwal M, Jha V, Jain D, Tarai B, et al. Differentials in the characteristics of COVID-19 cases in wave-1 and wave-2 admitted to a network of hospitals in North India [Preprint]. medRxiv [Internet]. 2021 Jun 27 [cited 2022 Oct 7];2021.06.24.21259438. Available from: https://www.medrxiv.org/content/10.1101/2021.06.24.21259438v1
- 584 54. Anscombe C, Lissauer S, Thole H, Rylance J, Dula D, Menyere M, et al. A


- comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study [Preprint]. medRxiv [Internet]. 2022 [cited 2022 Oct 7]; Available from: /pmc/articles/PMC9298135/
- 588 55. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al.
  Decreased severity of disease during the first global omicron variant covid-19
  outbreak in a large hospital in tshwane, south africa. Int J Infect Dis [Internet].
  2022 Mar 1 [cited 2022 Oct 7];116:38–42. Available from:
  https://pubmed.ncbi.nlm.nih.gov/34971823/
- 593 56. Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-594 19 mortality in Europe and Israel. Public Health. 2021 Sep 1;198(May):230–7.
- 595 57. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. 596 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl 597 J Med [Internet]. 2021 Aug 12 [cited 2022 Oct 7];385(7):585–94. Available from: 598 https://pubmed.ncbi.nlm.nih.gov/34289274/
- 58. Xavier CR, Oliveira RS, Vieira V da F, Lobosco M, Dos Santos RW.
  Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact
  of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa,
  Germany, and Brazil. BioTech [Internet]. 2022 Jun 1 [cited 2022 Oct 7];11(2).
  Available from: /pmc/articles/PMC9264399/

## List of Legends

604

605

- Table 1. Augmented Dicky-Fuller tests for unit roots
- Table 2. Descriptive characteristics of each COVID-19 wave
- Table 3. Ordinary least squares (OLS) regression results for COVID-19 deaths
- 609 Figure 1. COVID-19 waves and daily new cases
- 610 S1 Table. Calculated ratio variables and their descriptions



Figure